Neoantigen-Pulsed Autologous Dendritic Cell Vaccine Combined With Temozolomide for Newly Diagnosed Glioblastoma
NCT07365280
·
clinicaltrials.gov ↗
PHASE2
Phase
NOT_YET_RECRUITING
Status
78
Enrollment
INDUSTRY
Sponsor class
Conditions
Glioblastoma
Interventions
BIOLOGICAL:
Personalized Dendritic Cell Vaccine ZSNeo-DC1.1
DRUG:
Temozolomide (TMZ)
Sponsor
ZSky Biotech Inc